← Eichor
Study identifier: NCT04461444 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

Condition: Bardet-Biedl Syndrome · Alström Syndrome  ·  Sponsor: University Hospital, Strasbourg, France

PhaseNA
Planned participants350
Who can joinAll sexes, 4 Months to no upper limit
Healthy volunteersNo

About this study

ALMS and BBS syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus. There are to date no specific treatments available and limited information on the natural history of the diseases. the investigators aim to establish a French cohort for these diseases to improve patient care and assess the effect of actual therapies on quality of life. The purpose of this study is to establish a cohort of Bardet-Bield syndrome (BBS) and ALström syndrome (ALMS) patients in order to formalize and address questions concerning the in-depth natural clinical and biological history of the disease on the long term for a given patient, establish the impact on the quality of life of various clinical manifestations

This description comes directly from the study's public registry record.

Talk to the study team

Hélène DOLFFUS  ·  +33.3.69.55.19.55  ·  helene.dollfus@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Les Hôpitaux Universitaires de StrasbourgStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04461444